6 hrs ago
Pacific Business Times
Atara Biotherapeutics angles for $92M, but jobs are scarce
Atara is among a new breed of "virtual" biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations.
Thu Aug 28, 2014
Applied Clinical Trials
Amgen Submits Biologics License Application For Novel Investigational ...
Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 , a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol , or "bad" cholesterol, from the blood.1 The BLA for evolocumab contains data from approximately 6,800 patients, including more than ... (more)
Wed Aug 27, 2014
Applied Clinical Trials
FDA Grants Amgen Priority Review Designation For Ivabradine For The...
Ivabradine is an oral drug that inhibits the I f current in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 ... (more)
Why Amgen Stock Is A Long-Term Investment Opportunity
Amgen Inc. will continue to benefit from the growing demand for its products, and from its top-quality pipeline that should sustain long-term growth.
Mon Aug 25, 2014
Amgen Reaches New 12-Month High at $134.93
Amgen 's share price hit a new 52-week high during mid-day trading on Monday , Stock Ratings Network.com reports.
Thu Aug 21, 2014
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going?
Puma Biotech, a small development stage biopharmaceutical company, recently announced positive results in one of their Phase III trials.
Amgen Has Yet To Reach Its Potential, Despite Strong Gains
With shares of Amgen trading at near 52-week highs, investors are getting nervous about the next couple of quarters.
Mon Aug 18, 2014
Amgen Announces Positive Top-Line Results From Second Phase 3 Study...
The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone levels during an Efficacy Assessment Phase defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in ... (more)
Thu Aug 14, 2014
Thursday Sector Leaders: Utilities, Healthcare
The best performing sector as of midday Thursday is the Utilities sector, higher by 0.9%.
Amgen Reaches New 52-Week High at $132.52
Amgen reached a new 52-week high on Thursday , Analyst Ratings Network.com reports.
Thursday's ETF Movers: BBH, GXC
In trading on Thursday, the Biotech ETF is outperforming other ETFs, up about 1.4% on the day.
Biotech News Alert: GenSpera (OTCQB:GNSZ) to Present at Rodman &...
August 14, 2014 GenSpera, Inc. , a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference.
Wed Aug 13, 2014
Amgen Issues Voluntary Recall of AranespA (darbepoetin alfa) (500...
Amgen initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination.
Applied Clinical Trials
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of...
The 315-patient, open-label study evaluated single-agent Kyprolis for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma.
Tue Aug 12, 2014
Amgen Popular Amongst Latest 13F Filers
At Holdings Channel , we have reviewed the latest batch of the 43 most recent 13F filings for the 06/30/2014 reporting period, and noticed that Amgen was held by 16 of these funds.
Mon Aug 11, 2014
Amgen Sees Unusually High Options Volume
Amgen saw unusually large options trading on Monday. Stock traders acquired 23,340 call options on the company, AnalystRatings.Net reports.
Sat Aug 09, 2014
Amgen Given Average Recommendation of "Buy" by Brokerages
Amgen has been given an average recommendation of "Buy" by the twenty brokerages that are covering the company, AnalystRatings.Net reports .
Fri Aug 08, 2014
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals,...
To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
Wed Aug 06, 2014
Congrats on a great quarter - now, you're fired
Last week Amgen, one of the USA's biggest biotechnology companies, reported a sensational quarter.
Tue Aug 05, 2014
Aspire Data A Big Plus For Amgen And Celgene
Strong interim data Yesterday, Amgen released data from a planned interim analysis of the Aspire study that could lead to a significant sales boost.